GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Wohua Pharmaceutical Co Ltd (SZSE:002107) » Definitions » Beneish M-Score

Shandong Wohua Pharmaceutical Co (SZSE:002107) Beneish M-Score : -3.33 (As of Jun. 05, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Shandong Wohua Pharmaceutical Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.33 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Shandong Wohua Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

SZSE:002107' s Beneish M-Score Range Over the Past 10 Years
Min: -3.33   Med: -2.71   Max: -1.37
Current: -3.33

During the past 13 years, the highest Beneish M-Score of Shandong Wohua Pharmaceutical Co was -1.37. The lowest was -3.33. And the median was -2.71.


Shandong Wohua Pharmaceutical Co Beneish M-Score Historical Data

The historical data trend for Shandong Wohua Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Wohua Pharmaceutical Co Beneish M-Score Chart

Shandong Wohua Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.86 -2.85 -2.77 -2.63 -3.08

Shandong Wohua Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.69 -2.80 -2.96 -3.08 -3.33

Competitive Comparison of Shandong Wohua Pharmaceutical Co's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Wohua Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shandong Wohua Pharmaceutical Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shandong Wohua Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Shandong Wohua Pharmaceutical Co's Beneish M-Score falls into.



Shandong Wohua Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Shandong Wohua Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7088+0.528 * 1.0229+0.404 * 0.9216+0.892 * 0.8979+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0815+4.679 * -0.09429-0.327 * 1.0582
=-3.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was ¥90.8 Mil.
Revenue was 215.317 + 193.114 + 224.083 + 257.028 = ¥889.5 Mil.
Gross Profit was 157.004 + 135.931 + 168.815 + 194.831 = ¥656.6 Mil.
Total Current Assets was ¥698.3 Mil.
Total Assets was ¥1,161.8 Mil.
Property, Plant and Equipment(Net PPE) was ¥375.3 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0.0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥511.4 Mil.
Total Current Liabilities was ¥297.2 Mil.
Long-Term Debt & Capital Lease Obligation was ¥0.0 Mil.
Net Income was 9.667 + 1.366 + 20.197 + 11.755 = ¥43.0 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0.0 Mil.
Cash Flow from Operations was 54.487 + 37.371 + 35.951 + 24.718 = ¥152.5 Mil.
Total Receivables was ¥142.7 Mil.
Revenue was 235.281 + 261.969 + 249.253 + 244.221 = ¥990.7 Mil.
Gross Profit was 177.493 + 198.756 + 187.075 + 184.672 = ¥748.0 Mil.
Total Current Assets was ¥610.5 Mil.
Total Assets was ¥1,104.4 Mil.
Property, Plant and Equipment(Net PPE) was ¥403.0 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0.0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥526.7 Mil.
Total Current Liabilities was ¥266.8 Mil.
Long-Term Debt & Capital Lease Obligation was ¥0.2 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(90.827 / 889.542) / (142.727 / 990.724)
=0.102105 / 0.144063
=0.7088

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(747.996 / 990.724) / (656.581 / 889.542)
=0.754999 / 0.738111
=1.0229

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (698.292 + 375.271) / 1161.752) / (1 - (610.474 + 402.996) / 1104.443)
=0.07591 / 0.08237
=0.9216

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=889.542 / 990.724
=0.8979

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 402.996)) / (0 / (0 + 375.271))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(511.442 / 889.542) / (526.68 / 990.724)
=0.57495 / 0.531611
=1.0815

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 297.226) / 1161.752) / ((0.196 + 266.835) / 1104.443)
=0.255843 / 0.241779
=1.0582

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(42.985 - 0 - 152.527) / 1161.752
=-0.09429

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Shandong Wohua Pharmaceutical Co has a M-score of -3.33 suggests that the company is unlikely to be a manipulator.


Shandong Wohua Pharmaceutical Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Shandong Wohua Pharmaceutical Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Wohua Pharmaceutical Co (SZSE:002107) Business Description

Traded in Other Exchanges
N/A
Address
Fushou East Street, Chuangye Building, 2F, New and High-Tech Industrial Development Zone, Huaifang, Shandong, CHN, 261011
Shandong Wohua Pharmaceutical Co Ltd is a China-based company specializing in the field of cardio-cerebral vascular medicine. The company's main products consist of Xinkeshu tablets for the treatment of coronary heart disease; Naoxueshu oral liquid, promoting blood circulation by removing blood stasis; Hupo Xiaoshi granules for the treatment of urethral calculus, and Yuandu granules for the treatment of influenza, among others.
Executives
Zhao Jun Director
Liu Wen Yi Supervisors
Zhang Fa Zhong Supervisors
Zhang Ge Director
Ma Xing Chen Supervisors
Tian Kai Ji Directors, executives
Kong Xian Jun Supervisors

Shandong Wohua Pharmaceutical Co (SZSE:002107) Headlines

No Headlines